biostudies-literatureUnknown19(1)Shikdar S<h4>Background</h4>In the recent COVID19 pandemic, patients with hematological disorders were considered at high risk for severe disease. Limited data is available regarding the course of COVID19 infection in this subgroup.<h4>Case presentation</h4>We describe a case of a 32-year-old man with paroxysmal nocturnal hemoglobinuria (PNH) undergoing treatment with ravulizumab (Ultomiris) who presented with COVID19 infection. He experienced only mild symptoms and had a rapid recovery from COVID19 infection.<h4>Conclusion</h4>This case may demonstrate the beneficial effects of ravulizumab on complement mediated inflammatory damage linked with COVID19 infection especially in PNH patients.Thrombosis journal75https://www.ebi.ac.uk/biostudies/studies/S-EPMC8530370biostudies-literatureCOVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab.PMC8530370Borogovac AMohamad EKhawandanah MShikdar SfalseCOVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab.<h4>Background</h4>In the recent COVID19 pandemic, patients with hematological disorders were considered at high risk for severe disease. Limited data is available regarding the course of COVID19 infection in this subgroup.<h4>Case presentation</h4>We describe a case of a 32-year-old man with paroxysmal nocturnal hemoglobinuria (PNH) undergoing treatment with ravulizumab (Ultomiris) who presented with COVID19 infection. He experienced only mild symptoms and had a rapid recovery from COVID19 infection.<h4>Conclusion</h4>This case may demonstrate the beneficial effects of ravulizumab on complement mediated inflammatory damage linked with COVID19 infection especially in PNH patients.2021-01-01T00:00:00Z2021 Oct2025-04-20T01:09:34.497Z2025-02-19T01:26:05.967ZS-EPMC85303703467470710.1186/s12959-021-00330-6